Published on Friday, 28 October 2016 08:30
ABIVAX to Attend the Jefferies 2016 London Healthcare Conference
Paris, October 28th, 2016 - ABIVAX (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today announces that Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX, will attend the Jefferies 2016 London Healthcare Conference being held on November 16th and 17th at the Waldorf Hilton in London, UK.
The event will feature leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors. It will include concurrent tracks of company presentations, thematic panel discussions, and 1x1/small-group meetings.
ABIVAX’s lead product ABX464 is in Phase II clinical development for the treatment of HIV, and earlier this year started a second Phase IIa trial designed to demonstrate the long-lasting effect of ABX464. The product candidate has a unique mechanism that interrupts HIV replication and also targets HIV reservoir cells.
One-on-one meetings with Pr. Ehrlich can be arranged through Jefferies.